- 現金殖利率: 4.51%、總殖利率: 4.51%、5年平均現金配發率: 97.09%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 (10) | 2.94 | 82.61 | 2.12 | 65.62 | 0.00 | 0 | 72.11 | -9.3 | 0.00 | 0 | 72.11 | -9.3 |
| 2023 (9) | 1.61 | 0.0 | 1.28 | -20.0 | 0.00 | 0 | 79.50 | -20.0 | 0.00 | 0 | 79.50 | -20.0 |
| 2022 (8) | 1.61 | 30.89 | 1.60 | 6.67 | 0.00 | 0 | 99.38 | -18.51 | 0.00 | 0 | 99.38 | -18.51 |
| 2021 (7) | 1.23 | -23.13 | 1.50 | -16.67 | 0.00 | 0 | 121.95 | 8.4 | 0.00 | 0 | 121.95 | 8.4 |
| 2020 (6) | 1.60 | -27.93 | 1.80 | 0.0 | 0.00 | 0 | 112.50 | 38.75 | 0.00 | 0 | 112.50 | 38.75 |
| 2019 (5) | 2.22 | 48.0 | 1.80 | 12.5 | 0.00 | 0 | 81.08 | -23.99 | 0.00 | 0 | 81.08 | -23.99 |
| 2018 (4) | 1.50 | -11.24 | 1.60 | -23.81 | 0.00 | 0 | 106.67 | -14.16 | 0.00 | 0 | 106.67 | -14.16 |
| 2017 (3) | 1.69 | -53.95 | 2.10 | -32.26 | 0.00 | 0 | 124.26 | 47.11 | 0.00 | 0 | 124.26 | 47.11 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q4 (20) | 0.25 | -80.16 | -40.48 | 0.42 | -62.83 | 7.69 | 2.95 | 9.26 | 83.23 |
| 24Q3 (19) | 1.26 | 240.54 | 186.36 | 1.13 | 253.12 | 370.83 | 2.70 | 88.81 | 126.89 |
| 24Q2 (18) | 0.37 | -65.42 | -22.92 | 0.32 | -69.52 | -17.95 | 1.43 | 33.64 | 90.67 |
| 24Q1 (17) | 1.07 | 154.76 | 282.14 | 1.05 | 169.23 | 262.07 | 1.07 | -33.54 | 282.14 |
| 23Q4 (16) | 0.42 | -4.55 | 100.0 | 0.39 | 62.5 | 143.75 | 1.61 | 35.29 | 0.0 |
| 23Q3 (15) | 0.44 | -8.33 | -6.38 | 0.24 | -38.46 | -7.69 | 1.19 | 58.67 | -15.0 |
| 23Q2 (14) | 0.48 | 71.43 | 14.29 | 0.39 | 34.48 | 14.71 | 0.75 | 167.86 | -19.35 |
| 23Q1 (13) | 0.28 | 33.33 | -45.1 | 0.29 | 81.25 | -35.56 | 0.28 | -82.61 | -45.1 |
| 22Q4 (12) | 0.21 | -55.32 | -44.74 | 0.16 | -38.46 | -65.96 | 1.61 | 15.0 | 30.89 |
| 22Q3 (11) | 0.47 | 11.9 | 80.77 | 0.26 | -23.53 | 225.0 | 1.40 | 50.54 | 64.71 |
| 22Q2 (10) | 0.42 | -17.65 | 23.53 | 0.34 | -24.44 | 30.77 | 0.93 | 82.35 | 57.63 |
| 22Q1 (9) | 0.51 | 34.21 | 104.0 | 0.45 | -4.26 | 73.08 | 0.51 | -58.54 | 104.0 |
| 21Q4 (8) | 0.38 | 46.15 | 2.7 | 0.47 | 487.5 | 0.0 | 1.23 | 44.71 | -23.13 |
| 21Q3 (7) | 0.26 | -23.53 | -35.0 | 0.08 | -69.23 | -61.9 | 0.85 | 44.07 | -30.89 |
| 21Q2 (6) | 0.34 | 36.0 | 61.9 | 0.26 | 0.0 | 23.81 | 0.59 | 136.0 | -28.92 |
| 21Q1 (5) | 0.25 | -32.43 | -59.68 | 0.26 | -44.68 | -60.61 | 0.25 | -84.38 | -59.68 |
| 20Q4 (4) | 0.37 | -7.5 | 0.0 | 0.47 | 123.81 | 0.0 | 1.60 | 30.08 | 0.0 |
| 20Q3 (3) | 0.40 | 90.48 | 0.0 | 0.21 | 0.0 | 0.0 | 1.23 | 48.19 | 0.0 |
| 20Q2 (2) | 0.21 | -66.13 | 0.0 | 0.21 | -68.18 | 0.0 | 0.83 | 33.87 | 0.0 |
| 20Q1 (1) | 0.62 | 0.0 | 0.0 | 0.66 | 0.0 | 0.0 | 0.62 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025/3 | 0.94 | -13.75 | 81.02 | 2.87 | 43.2 | 2.87 | N/A | 本⽉營收較去年同期增加，係市場需求增加及⼦公司合併營收增加所致。 | ||
| 2025/2 | 1.09 | 30.24 | 217.56 | 1.93 | 29.96 | 2.94 | N/A | 本月營收較去年同期增加，主係市場需求增加及子公司合併營收增加所致。 | ||
| 2025/1 | 0.84 | -17.34 | -26.55 | 0.84 | -26.55 | 2.77 | N/A | - | ||
| 2024/12 | 1.01 | 10.22 | 41.16 | 11.16 | 37.58 | 2.91 | 0.6 | - | ||
| 2024/11 | 0.92 | -5.84 | 44.45 | 10.14 | 37.23 | 4.12 | 0.43 | - | ||
| 2024/10 | 0.98 | -56.05 | 7.56 | 9.22 | 36.55 | 4.09 | 0.43 | - | ||
| 2024/9 | 2.22 | 150.47 | 39.03 | 8.24 | 40.99 | 3.88 | 0.45 | - | ||
| 2024/8 | 0.89 | 15.22 | 45.52 | 6.02 | 41.73 | 2.35 | 0.74 | - | ||
| 2024/7 | 0.77 | 10.72 | 58.81 | 5.13 | 41.1 | 2.37 | 0.73 | 於民國一一三年四月九日取得高峰藥品材料股份有限公司及高峰生技股份有限公司各51%已發行流通在外普通股, 係以合併營業收入申報. | ||
| 2024/6 | 0.7 | -23.33 | 3.66 | 4.36 | 38.37 | 2.36 | 0.75 | - | ||
| 2024/5 | 0.91 | 20.54 | 65.0 | 3.67 | 47.77 | 2.18 | 0.81 | 於民國113年4月9日取得高峰藥品材料股份有限公司及高峰生技股份有限公司各51%已發行流通在外普通股，係以合併營業收入申報. | ||
| 2024/4 | 0.75 | 44.74 | 56.25 | 2.76 | 42.85 | 1.62 | 1.09 | 於民國一一三年四月九日取得高峰藥品材料股份有限公司及高峰生技股份有限公司各51%已發行流通在外普通股, 係以合併營業收入申報. | ||
| 2024/3 | 0.52 | 51.29 | -0.82 | 2.0 | 38.4 | 2.0 | 0.64 | - | ||
| 2024/2 | 0.34 | -69.87 | -23.09 | 1.48 | 60.66 | 2.21 | 0.58 | 因認列藥證移轉勞務收入與市場需求增加，故本年累計營收較去年同期增加。 | ||
| 2024/1 | 1.14 | 58.21 | 139.13 | 1.14 | 139.13 | 2.3 | 0.56 | 因適逢農曆春節連續假期備貨與藥證移轉勞務收入所致，故較去年同期增加。 | ||
| 2023/12 | 0.72 | 65.84 | 58.13 | 8.11 | 74.68 | 1.57 | 0.75 | 依據財務會計準則之相關規定，本公司併購創益公司，係屬集團內之組織重組，視為自始合併不受設立日之限制，故營收為合併淨額。 | ||
| 2023/11 | 0.43 | 4.27 | 11.55 | 4.53 | 8.19 | 1.28 | 0.92 | - | ||
| 2023/10 | 0.42 | -1.79 | 11.04 | 4.1 | 7.84 | 1.25 | 0.94 | - | ||
| 2023/9 | 0.42 | 4.01 | 3.48 | 3.68 | 7.49 | 1.24 | 1.21 | - | ||
| 2023/8 | 0.41 | 1.03 | 11.39 | 3.25 | 8.04 | 1.26 | 1.19 | - | ||
| 2023/7 | 0.4 | -9.74 | 17.25 | 2.85 | 7.57 | 1.27 | 1.18 | - | ||
| 2023/6 | 0.45 | 5.95 | 24.26 | 2.44 | 6.12 | 1.27 | 0.88 | - | ||
| 2023/5 | 0.42 | 6.49 | 15.8 | 1.99 | 2.75 | 1.23 | 0.91 | - | ||
| 2023/4 | 0.4 | -4.42 | 6.93 | 1.57 | -0.26 | 1.16 | 0.97 | - | ||
| 2023/3 | 0.42 | 19.85 | -1.94 | 1.17 | -2.47 | 1.17 | 0.94 | - | ||
| 2023/2 | 0.35 | -16.14 | 23.17 | 0.76 | -2.77 | 1.22 | 0.91 | - | ||
| 2023/1 | 0.41 | -9.43 | -17.36 | 0.41 | -17.36 | 1.26 | 0.88 | - | ||
| 2022/12 | 0.46 | 16.99 | 22.92 | 4.64 | 12.3 | 1.22 | 0.88 | - | ||
| 2022/11 | 0.39 | 3.8 | 7.69 | 4.19 | 11.26 | 1.18 | 0.91 | - | ||
| 2022/10 | 0.38 | -8.48 | 9.53 | 3.8 | 11.64 | 1.15 | 0.93 | - | ||
| 2022/9 | 0.41 | 11.96 | 16.24 | 3.42 | 11.87 | 1.12 | 0.56 | - | ||
| 2022/8 | 0.37 | 6.35 | 7.88 | 3.01 | 11.3 | 1.07 | 0.59 | - | ||
| 2022/7 | 0.34 | -4.34 | 16.53 | 2.65 | 11.79 | 1.07 | 0.59 | - | ||
| 2022/6 | 0.36 | -1.25 | 7.23 | 2.3 | 11.12 | 1.1 | 0.57 | - | ||
| 2022/5 | 0.36 | -1.66 | -0.36 | 1.94 | 11.87 | 1.16 | 0.53 | - | ||
| 2022/4 | 0.37 | -12.36 | 5.77 | 1.58 | 15.14 | 1.08 | 0.58 | - | ||
| 2022/3 | 0.42 | 50.56 | 8.84 | 1.2 | 18.38 | 1.2 | 0.51 | - | ||
| 2022/2 | 0.28 | -43.74 | 7.6 | 0.78 | 24.28 | 1.15 | 0.53 | - | ||
| 2022/1 | 0.5 | 34.72 | 36.15 | 0.5 | 36.15 | 1.23 | 0.49 | - | ||
| 2021/12 | 0.37 | 2.5 | -23.22 | 4.13 | -7.67 | 1.08 | 0.68 | - | ||
| 2021/11 | 0.36 | 5.57 | 2.73 | 3.76 | -5.79 | 1.06 | 0.69 | - | ||
| 2021/10 | 0.34 | -2.87 | -16.98 | 3.4 | -6.62 | 1.04 | 0.7 | - | ||
| 2021/9 | 0.35 | 3.9 | 17.21 | 3.06 | -5.29 | 0.99 | 0.74 | - | ||
| 2021/8 | 0.34 | 14.88 | -2.05 | 2.71 | -7.6 | 0.97 | 0.75 | - | ||
| 2021/7 | 0.3 | -11.98 | -16.57 | 2.37 | -8.35 | 1.0 | 0.73 | - | ||
| 2021/6 | 0.34 | -8.25 | 10.61 | 2.07 | -7.04 | 1.05 | 0.62 | - | ||
| 2021/5 | 0.37 | 4.39 | 37.68 | 1.73 | -9.83 | 1.11 | 0.59 | - | ||
| 2021/4 | 0.35 | -9.82 | 3.83 | 1.37 | -17.46 | 1.0 | 0.65 | - | ||
| 2021/3 | 0.39 | 48.85 | -8.88 | 1.02 | -22.91 | 1.02 | 0.74 | - | ||
| 2021/2 | 0.26 | -28.82 | -32.77 | 0.63 | -29.61 | 1.11 | 0.67 | - | ||
| 2021/1 | 0.37 | -24.03 | -27.18 | 0.37 | -27.18 | 1.2 | 0.62 | - | ||
| 2020/12 | 0.48 | 37.16 | 32.82 | 4.48 | -11.78 | 1.25 | 0.62 | - | ||
| 2020/11 | 0.35 | -14.69 | -13.6 | 4.0 | -15.22 | 1.07 | 0.73 | - | ||
| 2020/10 | 0.41 | 37.14 | -1.88 | 3.64 | -15.37 | 1.06 | 0.74 | - | ||
| 2020/9 | 0.3 | -13.17 | -38.32 | 3.23 | -16.84 | 1.0 | 0.88 | - | ||
| 2020/8 | 0.35 | -2.14 | -17.44 | 2.93 | -13.75 | 1.01 | 0.88 | - | ||
| 2020/7 | 0.35 | 16.7 | -12.58 | 2.58 | -13.22 | 0.92 | 0.95 | - | ||
| 2020/6 | 0.3 | 14.19 | -15.1 | 2.23 | -13.32 | 0.91 | 0.91 | - | ||
| 2020/5 | 0.27 | -21.26 | -35.32 | 1.92 | -13.04 | 0.0 | N/A | - | ||
| 2020/4 | 0.34 | -29.19 | -21.77 | 1.66 | -7.95 | 0.0 | N/A | - |
